Candriam Luxembourg S.C.A. decreased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 9.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 69,610 shares of the medical instruments supplier’s stock after selling 7,239 shares during the period. Candriam Luxembourg S.C.A.’s holdings in DENTSPLY SIRONA were worth $4,514,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ropes Wealth Advisors LLC increased its position in shares of DENTSPLY SIRONA by 0.3% in the first quarter. Ropes Wealth Advisors LLC now owns 9,003 shares of the medical instruments supplier’s stock valued at $562,000 after buying an additional 29 shares during the period. HighTower Advisors LLC increased its position in shares of DENTSPLY SIRONA by 0.6% in the first quarter. HighTower Advisors LLC now owns 6,823 shares of the medical instruments supplier’s stock valued at $424,000 after buying an additional 39 shares during the period. Atria Investments LLC increased its position in shares of DENTSPLY SIRONA by 1.5% in the second quarter. Atria Investments LLC now owns 4,541 shares of the medical instruments supplier’s stock valued at $294,000 after buying an additional 68 shares during the period. Creative Planning increased its position in shares of DENTSPLY SIRONA by 1.0% in the first quarter. Creative Planning now owns 6,800 shares of the medical instruments supplier’s stock valued at $425,000 after buying an additional 70 shares during the period. Finally, Northwest Wealth Management LLC increased its position in shares of DENTSPLY SIRONA by 1.4% in the first quarter. Northwest Wealth Management LLC now owns 5,834 shares of the medical instruments supplier’s stock valued at $364,000 after buying an additional 80 shares during the period. Hedge funds and other institutional investors own 95.17% of the company’s stock.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Tuesday, May 9th. The medical instruments supplier reported $0.49 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.50 by $0.01. DENTSPLY SIRONA had a net margin of 9.42% and a return on equity of 7.37%. The business had revenue of $900.50 million during the quarter, compared to analyst estimates of $916.55 million. During the same quarter in the prior year, the business earned $0.69 earnings per share. The firm’s quarterly revenue was up 16.6% on a year-over-year basis.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 13th. Shareholders of record on Friday, September 29th will be paid a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Thursday, September 28th. DENTSPLY SIRONA’s dividend payout ratio is presently 22.58%.

COPYRIGHT VIOLATION WARNING: “DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Sold by Candriam Luxembourg S.C.A.” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/07/dentsply-sirona-inc-nasdaqxray-shares-sold-by-candriam-luxembourg-s-c-a.html.

Several brokerages recently weighed in on XRAY. Cleveland Research upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating in a research note on Tuesday, May 23rd. Zacks Investment Research upgraded DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a research note on Wednesday, April 19th. BidaskClub downgraded DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research note on Saturday, June 10th. HC Wainwright began coverage on DENTSPLY SIRONA in a research note on Tuesday, July 11th. They set a “buy” rating and a $74.00 target price on the stock. Finally, Goldman Sachs Group, Inc. (The) downgraded DENTSPLY SIRONA from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $60.00 to $55.00 in a research note on Tuesday, May 23rd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $67.92.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.